Quarterly report pursuant to Section 13 or 15(d)

Segment Information

v3.8.0.1
Segment Information
6 Months Ended
Feb. 28, 2018
Segment Information [Text Block]
15.

Segment Information

   
 

The Company’s operations involve the development and usage, including licensing, of its proprietary nutrient infusion Technology. Lexaria is centrally managed and its chief operating decision makers, being the president and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified two reportable segments: Intellectual Property Licensing and Consumer Products. Licensing revenues are significantly concentrated on a single licensee.


    IP Licensing Consumer Products Corporate Consolidated Total
  External Revenue 184,083 12,510 - 196,593
  Cost of Goods Sold - (19,812) - (19,812)
  Operating Expenses (384,243) (89,351) (1,660,278) (2,133,872)
  Segment Loss (200,160) (96,653) (1,660,278) (1,957,091)
  Total Assets 94,341 64,073 2,682,826 2,841,240